References
- Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 25(2), 109–127 (2011).
- Lyoo IK, Yoon S, Kim TS et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am. J. Psychiatry 169(9), 937–945 (2012).
- Janowsky DS, Overstreet DH. Cholinergic dysfunction in depression. Pharmacol. Toxicol. 66(Suppl. 3), 100–111 (1990).
- Khajavi D, Farokhnia M, Modabbernia A et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 73(11), 1428–1433 (2012).
- Chew ML, Mulsant BH, Pollock BG et al. Anticholinergic activity of 107 medications commonly used by older adults. J. Am. Geriatr. Soc. 56(7), 1333–1341 (2008).
- Trumic E, Pranjic N, Begic L, Becic F, Asceric M. Idiosyncratic adverse reactions of most frequent drug combinations longterm use among hospitalized patients with polypharmacy. Med. Arh. 66(4), 243–248 (2012).
- Kumar S, Kulkarni SK. Influence of antidepressant drugs on learning and memory paradigms in mice. Indian J. Exp. Biol. 34(5), 431–435 (1996).
- Pae CU, Sohi MS, Seo HJ et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(7), 1165–1173 (2010).
- Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am. J. Psychiatry 152(10), 1500–1503 (1995).
- Rush AJ, Warden D, Wisniewski SR et al. STAR*D: revising conventional wisdom. CNS Drugs 23(8), 627–647 (2009).
- Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 30(3), 148–155 (2009).
- Drapier D, Péron J, Leray E et al. Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson’s disease have separate neural substrates. Neuropsychologia 46(11), 2796–2801 (2008).
- Tayebati SK, Amenta F, El-Assouad D, Zaccheo D. Muscarinic cholinergic receptor subtypes in the hippocampus of aged rats. Mech. Ageing Dev. 123(5), 521–528 (2002).